Trial
NCT05055258
A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
KalVista Pharmaceuticals, Ltd.
Collaborators
—
Condition
Angioedema, Hereditary, Types I and II
Intervention
KVD824
Why stopped
Terminated by Sponsor due to adverse events reported
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-06